Table 1.
Correlation between YAP1 expression and clinicopathological parameters in ESCC.
| Han | P value | Kazakh | P value | Uygur | P value | Total | P value | |||||
| Clinicopathological parameters | YAP1 | YAP1 | YAP1 | YAP1 | ||||||||
| Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | |||||
| Gender | ||||||||||||
| Male | 38 (65.5%) | 14 (82.4%) | .24 | 49 (60.5%) | 16 (66.7%) | .584 | 63 (67.7%) | 9 (75%) | .749 | 150 (64.7%) | 39 (73.6%) | .215 |
| Female | 20 (34.5%) | 3 (17.6%) | 32 (39.5%) | 8 (33.3%) | 30 (32.3%) | 3 (25%) | 82 (35.3%) | 14 (26.4%) | ||||
| Age | ||||||||||||
| <60 | 10 (17.2%) | 4 (23.5%) | .724 | 33 (40.7%) | 11 (45.8%) | .657 | 54 (58.1%) | 6 (50%) | .595 | 97 (41.8%) | 21 (39.6%) | .77 |
| ≥60 | 48 (82.8%) | 13 (76.5%) | 48 (59.3%) | 13 (54.2%) | 39 (41.9%) | 6 (50%) | 135 (58.2%) | 32 (60.4%) | ||||
| Tumor size | ||||||||||||
| <3 cm | 12 (20.7%) | 9 (52.9%) | .004 | 25 (30.9%) | 8 (33.3%) | .891 | 28 (30.1%) | 6 (50%) | .197 | 65 (28%) | 23 (43.4%) | .029 |
| ≥3 cm | 46 (79.3%) | 8 (47.1%) | 56 (69.1%) | 16 (67.7%) | 65 (69.9%) | 6 (50%) | 167 (72%) | 30 (56.6%) | ||||
| Degree of differentiation | ||||||||||||
| Poorly differentiated | 2 (3.4%) | 3 (17.6%) | .086 | 8 (9.9%) | 8 (33.3%) | .017 | 6 (6.5%) | 4 (33.3%) | .016 | 16 (6.9%) | 15 (28.3%) | .0001 |
| Moderately differentiated | 38 (65.5%) | 11 (64.8%) | 36 (44.4%) | 9 (37.5%) | 67 (72%) | 5 (41.7%) | 141 (60.8%) | 25 (47.2%) | ||||
| Well differentiated | 18 (31.1%) | 3 (17.6%) | 37 (45.7%) | 7 (29.2%) | 20 (21.5%) | 3 (25%) | 75 (32.3%) | 13 (24.5%) | ||||
| Depth of invasion | ||||||||||||
| Mucosa | 5 (8.6%) | 2 (11.8%) | .914 | 0 (0%) | 4 (16.7%) | .000 | 0 (0%) | 1 (8.3%) | .43 | 5 (2.2%) | 7 (13.2%) | .001 |
| Muscularis | 26 (43.1%) | 7 (41.2%) | 36 (44.4%) | 14 (16.7%) | 45 (48.4%) | 3 (25%) | 107 (46.1%) | 24 (45.2%) | ||||
| Full-thickness | 27 (46.5%) | 8 (47%) | 45 (55.6%) | 6 (66.6%) | 48 (51.6%) | 8 (66.7%) | 120 (51.7%) | 22 (41.5%) | ||||
| TNM stage | ||||||||||||
| IA + B | 13 (22.4%) | 6 (35.3%) | .504 | 16 (19.8%) | 4 (16.7%) | .003 | 27 (29%) | 6 (50%) | .012 | 56 (24.1%) | 16 (30.2%) | .0001 |
| IIA + B | 28 (48.3%) | 5 (29.4%) | 60 (74.1%) | 12 (50%) | 59 (63.4%) | 3 (25%) | 147 (63.4%) | 20 (37.8%) | ||||
| IIIA + B | 5 (8.6%) | 2 (11.8%) | 5 (6.1%) | 8 (33.3%) | 4 (4.3%) | 3 (25%) | 14 (6.0%) | 13 (24.5%) | ||||
| IVA + B | 12 (20.7%) | 4 (23.5%) | 0 (0%) | 0 (0%) | 3 (3.2%) | 0 (0%) | 15 (6.5%) | 4 (7.5%) | ||||
| Lymph node metastasis | ||||||||||||
| Yes | 24 (41.4%) | 4 | .181 | 22 (27.5%) | 4 (16.7%) | .282 | 34 (36.6%) | 3 (25%) | .533 | 80 (34.6%) | 11 (20.8%) | .051 |
| No | 34 (58.6%) | 13 | 58 (72.5%) | 20 (83.3%) | 59 (63.4%) | 9 (75%) | 151 (65.4%) | 42 (79.2%) | ||||
| Vascular invasion | ||||||||||||
| Yes | 8 (13.8%) | 2 (11.8%) | 1 | 6 (7.4%) | 8 (33.3%) | .003 | 18 (19.6%) | 3 (25%) | .705 | 32 (13.8%) | 13 (24.5%) | .055 |
| No | 50 (86.2%) | 15 (88.2%) | 75 (92.6%) | 16 (66.7%) | 74 (80.4%) | 9 (75%) | 199 (86.2%) | 40 (75.5%) | ||||
| Nerve invasion | ||||||||||||
| Yes | 6 (10.3%) | 2 (11.8%) | 1 | 24 (29.6%) | 4 (16.7%) | .207 | 15 (16.1%) | 3 (25%) | .428 | 45 (19.4%) | 9 (17%) | .686 |
| No | 52 (89.7%) | 15 (88.2%) | 57 (70.4%) | 20 (83.3%) | 78 (83.9%) | 9 (75%) | 187 (80.6%) | 44 (83%) | ||||
| Ethnic | ||||||||||||
| Han | 58 (25.6%) | 17 (29.3%) | ||||||||||
| Kazakh | 81 (35.7%) | 24 (41.4%) | .059 | |||||||||
| Uygur | 93 (38.7%) | 12 (29.3%) | ||||||||||
(Unorganized absence).
ESCC = esophageal squamous cell carcinoma, YAP1 = yes related protein 1.